They write…. The Psychedelics as Medicine Report presents unparalleled insights and intelligence into this emerging movement, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
KEY FINDINGS FROM THE REPORT INCLUDE:
While cannabis has already paved much of the way for psychedelics in terms of legal progress and changing public perception, psychedelics as medicines are already backed by a more powerful knowledge base comparatively.
North America and Europe are home to 142 active, or soon-to-be active, clinical trials focused on the therapeutic potential of psychedelic substances.
Psychedelics appear set to become the next major innovation for treating several high-prevalence mental health problems, such as PTSD and major depressive disorder, which together affect upwards of 350 million people worldwide.
Some psychedelics are already commonly used as therapeutic medicines, with others recently being awarded ‘breakthrough therapy’ status.
Unsurprisingly the event follows in June